| ［1］ Marsili G, Perrotti E, Remoli AL, et al. IFN regulatory factors and
antiviral innate immunity: how viruses can get better［J］. J Interferon
Cytokine Res, 2016, 36(7): 414-432. DOI: 10.1089/jir.2016.0002.
［2］ Yanai H, Negishi H, Taniguchi T. The IRF family of transcription
factors: inception, impact and implications in oncogenesis［J］.
Oncoimmunology, 2012, 1(8): 1376-1386. DOI: 10.4161/onci.22475.
［3］ Tarassishin L, Bauman A, Suh HS, et al. Antiviral and
antiinflammatory mechanisms of the innate immune transcription factor
interferon regulatory factor 3: relevance to human CNS diseases［J］. J
Neuroimmune Pharmacol, 2013, 8(1): 132-144. DOI: 10.1007/s114810129360
5.
［4］ Ikushima H, Negishi H, Taniguchi T. The IRF family transcription
factors at the interface of innate and adaptive immune responses［J］. Cold
Spring Harb Symp Quant Biol, 2013, 78(78): 105-116. DOI:
10.1101/sqb.2013.78.020321.
［5］ Zhao GN, Jiang DS, Li H. Interferon regulatory factors: at the
crossroads of immunity, metabolism, and disease［J］. Biochim Biophys Acta,
2015, 1852(2): 365-378. DOI: 10.1016/j.bbadis.2014.04.030.
［6］ Grandvaux N, Guan X, Yoboua F, et al. Sustained activation of
interferon regulatory factor 3 during infection by paramyxoviruses requires
MDA5［J］. J Innate Immun, 2014, 6(5): 650-662. DOI: 10.1159/000360764.
［7］ Andzinski L, Spanier J, Kasnitz N, et al. Growing tumors induce a
local STING dependent Type Ⅰ IFN response in dendritic cells［J］. Int J
Cancer, 2016, 139(6): 1350-1357. DOI: 10.1002/ijc.30159.
［8］ SterneWeiler T, Sanford JR. Exon identity crisis: diseasecausing
mutations that disrupt the splicing code［J］. Genome Biol, 2014, 15(1):
201. DOI: 10.1186/gb4150.
［9］ Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in
human tissue transcriptomes［J］. Nature, 2008, 456(7221): 470-476. DOI:
10.1038/nature07509.
［10］ Wiszomirska H, PiekiekoWitkowska A, Nauman A. Disturbances of
alternative splicing in cancer［J］. Postepy Biochem, 2011, 57(3):
257-265.
［11］ Abou Faycal C, Gazzeri S, Eymin B. RNA splicing, cell signaling, and
response to therapies［J］. Curr Opin Oncol, 2016, 28(1): 58-64. DOI:
10.1097/CCO.0000000000000254.
［12］ BiselliChicote PM, Oliveira AR, Pavarino EC, et al. VEGF gene
alternative splicing: pro and antiangiogenic isoforms in cancer［J］. J
Cancer Res Clin Oncol, 2012, 138(3): 363-370. DOI:
10.1007/s0043201110732.
［13］ Anczuków O, Krainer AR. Splicingfactor alterations in cancers［J］
. RNA, 2016, 22(9): 1285-1301. DOI: 10.1261/rna.057919.116.
［14］ Li Y, Hu X, Song Y, et al. Identification of novel alternative
splicing variants of interferon regulatory factor 3［J］. Biochim Biophys
Acta, 2011, 1809(3): 166-175. DOI: 10.1016/j.bbagrm.2011.01.006.
［15］ Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival
mechanism of cancer cells［J］. Semin Cancer Biol, 2012, 22(3): 194-207.
DOI: 10.1016/j.semcancer.2012.02.013.
［16］ Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016［J］. Cell, 2016,
166(1): 21-45. DOI: 10.1016/j.cell.2016.06.028.
［17］ Gao D, Vahdat LT, Wong S, et al. Microenvironmental regulation of
epithelialmesenchymal transitions in cancer［J］. Cancer Res, 2012, 72
(19): 4883-4889. DOI: 10.1158/00085472.CAN121223.
［18］ Xu P, BaileyBucktrout S, Xi Y, et al. Innate antiviral host
defense attenuates TGFβ function through IRF3mediated suppression of
Smad signaling［J］. Mol Cell, 2014, 56(6): 723-737. DOI:
10.1016/j.molcel.2014.11.027.
［19］ Zhu S, Li HB, Flavell RA. Resemble and inhibit: when RLR meets TGF
beta［J］. Mol Cell, 2014, 56(6): 719-720. DOI:
10.1016/j.molcel.2014.12.010.
［20］ Pythoud C, Rothenberger S, MartínezSobrido L, et al. Lymphocytic
choriomeningitis virus differentially affects the virusinduced type Ⅰ
interferon response and mitochondrial apoptosis mediated by RIGⅠ/MAVS［J
］. J Virol, 2015, 89(12): 6240-6250. DOI: 10.1128/JVI.0061015.
［21］ Yuan MM, Xu YY, Chen L, et al. TLR3 expression correlates with
apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and
predicts prognosis［J］. BMC Cancer, 2015, 15: 245. DOI:
10.1186/s1288501512625.
［22］ Gambara G, Desideri M, Stoppacciaro A, et al. TLR3 engagement
induces IRF3dependent apoptosis in androgensensitive prostate cancer
cells and inhibits tumour growth in vivo［J］. J Cell Mol Med, 2015, 19(2):
327-339. DOI: 10.1111/jcmm.12379.
［23］ Mantovani A. Molecular pathways linking inflammation and cancer［J］
. Curr Mol Med, 2010, 10(4): 369-373.
［24］ Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in
cancer［J］. Adv Cancer Res, 2010, 107: 57-117. DOI: 10.1016/S0065230X
(10)07003X.
［25］ Guo R, Li Y, Ning J, et al. HnRNP A1/A2 and SF2/ASF regulate
alternative splicing of interferon regulatory factor3 and affect
immunomodulatory functions in human nonsmall cell lung cancer cells［J］.
PLoS One, 2013, 8(4): e62729. DOI: 10.1371/journal.pone.0062729.
［26］ Szabo A, Fekete T, Koncz G, et al. RIGⅠ inhibits the
MAPKdependent proliferation of BRAF mutant melanoma cells via MKP1［J］
. Cell Signal, 2016, 28(5): 335-347. DOI: 10.1016/j.cellsig.2016.01.012.
［27］ Duewell P, Beller E, Kirchleitner SV, et al. Targeted activation of
melanoma differentiationassociated protein 5 (MDA5) for immunotherapy of
pancreatic carcinoma［J］. Oncoimmunology, 2015, 4(10): e1029698. DOI:
10.1080/2162402X.2015.1029698.
［28］ Liu B, Wang X, Chen TZ, et al. Polarization of M1 tumor associated
macrophage promoted by the activation of TLR3 signal pathway［J］. Asian
Pac J Trop Med, 2016, 9(5): 484-488. DOI: 10.1016/j.apjtm.2016.03.019.
［29］ Liu Y, Li T, Xu Y, et al. Effects of TLR4 gene silencing on the
proliferation and apotosis of hepatocarcinoma HEPG2 cells［J］. Oncol Lett,
2016, 11(5): 3054-3060.
［30］ Muvaffak A, Pan Q, Yan H, et al. Evaluating TBK1 as a therapeutic
target in cancers with activated IRF3［J］. Mol Cancer Res, 2014, 12(7):
1055-1066. DOI: 10.1158/15417786.MCR130642. |
